Neuron23 Company
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Technology:
Health Care, Medical
Industry:
Early Drug Development, Preclinical Development
Headquarters:
San Francisco, California, United States
Founded Date:
2018-01-01
Employees Number:
11-50
Funding Status:
Late Stage Venture
Investors Number:
10
Total Funding:
213500000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-03-30
Last Funding Type:
Series C
Register and Claim Ownership